Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CorMedix Inc CRMD

Healthcare
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections... see more

Recent & Breaking News (NDAQ:CRMD)

CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

GlobeNewswire November 4, 2024

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

GlobeNewswire October 30, 2024

CorMedix Inc. Announces New Data at ASN Kidney Week 2024

GlobeNewswire October 24, 2024

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

GlobeNewswire October 23, 2024

CorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator

GlobeNewswire October 8, 2024

CorMedix Inc. Announces New Commercial Agreement

GlobeNewswire September 19, 2024

CorMedix Inc. to Present at the Cantor Global Healthcare Conference

GlobeNewswire September 13, 2024

CorMedix Inc. Announces New Commercial Agreement

GlobeNewswire September 9, 2024

CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update

GlobeNewswire August 14, 2024

CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024

GlobeNewswire August 7, 2024

CorMedix Inc. Announces Outpatient Availability of DefenCath

GlobeNewswire July 3, 2024

CorMedix Inc. Receives FDA Feedback on Potential Label Expansion

GlobeNewswire June 18, 2024

CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath

GlobeNewswire June 6, 2024

CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider

GlobeNewswire May 28, 2024

CorMedix Inc. to Participate in Two Upcoming Investor Conferences

GlobeNewswire May 10, 2024

CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 9, 2024

CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024

GlobeNewswire May 6, 2024

CorMedix Inc. Announces CMS Grants TDAPA to DefenCath

GlobeNewswire April 19, 2024

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)

GlobeNewswire April 15, 2024

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

GlobeNewswire April 11, 2024